Edition:
United States

Cytori Therapeutics Inc (CYTX.OQ)

CYTX.OQ on NASDAQ Stock Exchange Capital Market

0.29USD
20 Apr 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$0.29
Open
$0.29
Day's High
$0.29
Day's Low
$0.28
Volume
39,991
Avg. Vol
236,505
52-wk High
$1.21
52-wk Low
$0.22

Select another date:

Fri, Mar 16 2018

BRIEF-Cytori Therapeutics - Co Met With U.S. FDA To Discuss Outcome Of Star Clinical Trial

* CYTORI THERAPEUTICS - ON MARCH 1, CO MET WITH U.S. FDA TO DISCUSS OUTCOME OF STAR CLINICAL TRIAL AND CO'S PLANS FOR HABEO CELL THERAPY - SEC FILING

BRIEF-Cytori Q4 Adjusted Loss Per Share $0.10

* CYTORI REPORTS FOURTH QUARTER AND FULL YEAR 2017 BUSINESS AND FINANCIAL RESULTS

BRIEF-Cytori Therapeutics Says David Rickey And Gail Naughton Submitted Resignations As Members Of Board

* CYTORI THERAPEUTICS - ON JAN 25, AS PART OF ONGOING RESTRUCTURING DAVID M. RICKEY AND GAIL K. NAUGHTON, SUBMITTED RESIGNATIONS AS MEMBERS OF BOARD

BRIEF-Swissquote Bank Sells 188,426 Shares Of Cytori Therapeutics Inc's Common Stock Between Jan 9-11

* SWISSQUOTE BANK SA REPORTS OPEN MARKET SALE OF 188,426 SHARES OF CYTORI THERAPEUTICS INC'S COMMON STOCK BETWEEN JAN 9 AND JAN 11 - SEC FILING Source text: (http://bit.ly/2ExdrAg) Further company coverage:

BRIEF-Swissquote Bank SA Reports 12 pct Passive Stake In Cytori Therapeutics As Of Dec. 29, 2017

* SWISSQUOTE BANK SA REPORTS 12 PERCENT PASSIVE STAKE IN CYTORI THERAPEUTICS INC AS OF DECEMBER 29, 2017 - SEC FILING‍​ Source text - (http://bit.ly/2CUutMr) Further company coverage:

BRIEF-Cytori Therapeutics Inc ‍announces new investigator initiated U.S. clinical trial for hip osteonecrosis​

* Cytori Therapeutics Inc - ‍announced a new investigator initiated U.S. clinical trial for hip osteonecrosis​ Source text for Eikon: Further company coverage:

BRIEF-Cytori reports Q3 loss per share $0.14

* Cytori reports third quarter 2017 business and financial results

Select another date: